Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

EU regulator warns of 'disappointing' vaccine booster uptake

Stock Markets Nov 24, 2022 10:05AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A health worker prepares a booster dose of a coronavirus disease (COVID-19) vaccine, as vaccinations jump in Italy after the government made inoculation mandatory for all workers, in Rome, Italy, September 21, 2021. REUTERS/Yara Nardi

By Ludwig Burger and Maggie Fick

(Reuters) -Recent uptake of COVID-19 vaccine booster doses in the European Union has been "rather disappointing," an official said on Thursday, amid concerns that protection against severe cases of the disease could weaken during the winter.

The European average rate of re-vaccination, or receiving booster doses, was only 29% in the groups of people considered to be at highest risk, such as the elderly and immunocompromised.

"It is of concern that those most at risk of hospitalisation or severe COVID are not adequately protected," the European Medicines Agency's head of health threats and vaccines strategy, Marco Cavaleri, told a news briefing.

Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months.

WHO data released late on Wednesday showed that 724,000 new COVID-19 cases were reported in the EU over the past week, down 11% from the previous week. In early October, when experts were warning of a new COVID-19 wave, the number of weekly cases reached 1.5 million.

"This virus is maintaining a fast pace in its evolution, and new subvariants of Omicron and its offspring are on the rise," Cavaleri said, adding that these are more resistant to vaccines.

NEW ANTIBODY TREATMENTS NEEDED

Cavaleri said it was worrisome that available antibody treatments to fight the virus in infected patients are no longer working against new subvariants.

The EMA intends to issue new guidelines for health care providers on the issue of such treatments, he said.

Last week, Britain’s agency that determines if medicines should be used in the National Health Service (NHS) said it recommended stopping the use of five COVID-19 treatments, including Merck & Co's's antiviral pill for high-risk patients, citing cost-effectiveness concerns.

In January, the U.S. Food and Drug Administration (FDA) also limited the use of some of these treatments due to data showing reduced effectiveness against the Omicron variant.

Cavaleri said that the EMA is in contact with companies working on next-generation monoclonal antibodies against COVID-19 to help speed up development.

The EU regulator would discuss this issue, including clinical trial design of next-generation treatments, at a meeting with the U.S. Food and Drug Administration and other international experts in December, he added.

An antiviral drug that is proving effective against all COVID-19 variants and subvariants is Pfizer Inc (NYSE:PFE)'s Paxlovid, he said. The drug has also been shown to prevent post-acute, longer-term effects of the disease, he added.

But prompt access to Paxlovid remains an issue in the EU, and the EMA is working with governments to change this, he said.

The agency's chief medical officer, Steffen Thirstrup, warned that a decline in case numbers over the past few weeks should not create a false sense of security as a rebound in cases could easily put vulnerable groups at risk again.

"Although many societies have opened up and are more or less considered to be back to normal, there is still a lot of circulating virus out there," Thirstrup said.

The Biden administration said earlier this month that the United States will keep in place the public health emergency status of the pandemic, instead of letting it expire in January.

Officials cited the possibility of a winter surge in COVID cases and the need for more time to transition out of the public health emergency to a private market as two factors that contributed to the decision.

EU regulator warns of 'disappointing' vaccine booster uptake
 

Related Articles

Airbus may delay some 2023 jet deliveries: sources
Airbus may delay some 2023 jet deliveries: sources By Reuters - Nov 27, 2022

By Tim Hepher PARIS (Reuters) - Airbus is preparing the ground for further delays to planned delivery dates of some medium-haul aircraft in 2023 even as it races to meet delivery...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email